SAN DIEGO, May 22, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the online publication of a new article1 in The Journal of General Virology detailing results from the company’s completed mouse studies with the company’s Vaxfectin®-formulated plasmid DNA (pDNA) vaccines against herpes simplex virus type 2 (HSV-2). These results, along with previously presented results from guinea pig studies, support the company’s decision in early 2012 to advance toward clinical testing, which is expected to begin in 2013.
